Aclaris Therapeutics, Inc.

ACRS

Aclaris Therapeutics, Inc.

ACRS

Insider Sentiment (TTM):

Last Purchase:2024-11-19Last Sale:2026-04-23Shares Purchased (TTM):0Shares Sold (TTM):300,000

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:106,034,675Shares Outstanding:128,810,050Institutional Ownership Pct.:82.32%

Earnings Market Reaction:

Filing Date:2026-05-07Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	29	20	25	25	30	25	48	23	36	40	39	31
Available For Sale Securities Debt Securities Curr…	77	71	71	74	75	89	80	88	92	79	64	89
Accounts Receivable Net Current	-	-	-	0	0	0	0	0	0	0	0	0
Prepaid Expense And Other Assets Current	-	-	-	4	3	12	4	6	7	9	20	13
Assets Current	110	96	101	104	109	126	132	118	135	129	123	133
Available For Sale Securities Debt Securities Nonc…	85	61	71	81	85	90	46	39	33	63	84	91
Property Plant And Equipment Net	1	1	1	1	1	1	1	1	2	2	2	2
Intangible Assets Net Excluding Goodwill	-	-	-	-	-	-	-	-	-	0	7	7
Other Assets Noncurrent	2	3	3	3	3	3	3	3	4	4	3	3
Assets	199	160	176	189	198	220	182	161	174	197	218	236
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	15	13	9	9	6	5	8	7	11	9	10	11
Accrued Liabilities Current	6	9	10	11	9	20	5	6	7	19	15	9
Contract With Customer Liability Current	4	4	4	4	4	4	4	-	-	-	-	-
Other Liabilities Current	3	3	3	3	3	3	3	3	3	3	-	-
Operating Lease Liability Current	-	-	-	-	-	-	-	-	-	0	0	0
Liabilities Current	27	29	26	27	22	32	19	16	20	31	27	23
Liabilities Of Disposal Group Including Discontinu…	-	-	-	-	-	-	-	-	-	2	2	2
Other Liabilities Noncurrent	1	2	2	2	4	4	2	2	3	3	2	2
Contract With Customer Liability Noncurrent	15	16	17	18	19	20	21	-	-	-	-	-
Business Combination Contingent Consideration Liab…	11	11	11	11	9	9	10	9	9	6	33	31
Deferred Income Tax Liabilities Net	-	-	-	-	-	-	-	-	-	-	0	0
Liabilities	55	57	55	57	54	65	52	27	32	40	62	56
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,131	1,070	1,067	1,065	1,062	1,058	936	933	930	928	927	921
Accumulated Other Comprehensive Income Loss Net Of…	0	1	1	0	0	0	0	-0	-0	-0	-1	-1
Retained Earnings Accumulated Deficit	-988	-968	-948	-933	-918	-903	-806	-799	-788	-771	-769	-740
Stockholders Equity	144	103	120	132	144	156	130	134	142	157	156	180
Liabilities And Stockholders Equity	199	160	176	189	198	220	182	161	174	197	218	236
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	400	400	400	400	400	400	400	400	400	400	400	400
Common Stock Shares Issued	140	120	108	108	108	108	71	71	71	71	71	71
Shares Outstanding	140	120	108	108	108	108	71	71	71	71	71	71

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-6.38%	2.88%	7.61%	-	-	-	-	-	-	-	-	-
2025	11.45%	12.21%	29.77%	22.93%	26.75%	36.94%	24.67%	33.48%	98.24%	17.89%	35.78%	44.41%
2024	-23.13%	-17.91%	3.73%	-0.84%	-1.68%	42.02%	80.09%	20.80%	11.06%	-17.95%	-41.54%	-32.82%
2023	4.64%	23.45%	16.90%	-13.57%	-25.05%	-51.64%	-83.50%	-80.84%	-77.55%	-4.17%	3.33%	-0.83%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	4.03	3.36	3.92	3.88	5.06	3.99	7.03	7.50	6.74	4.16	4.50	5.82
Quick Ratio	4.03	3.36	3.92	3.73	4.91	3.61	6.81	7.10	6.40	3.86	3.78	5.27
Working Capital	82.86M	67.67M	74.96M	77.36M	87.28M	94.36M	113.51M	101.95M	115.26M	97.90M	95.75M	110.11M
Leverage & Debt
Debt to Equity	0.38	0.56	0.46	0.44	0.38	0.42	0.40	0.20	0.23	0.26	0.40	0.31
Debt Ratio	0.28	0.36	0.32	0.30	0.27	0.29	0.29	0.17	0.18	0.20	0.28	0.24
Efficiency & Turnover
Asset Turnover TTM	0.04	0.04	0.09	0.10	0.10	0.09	0.14	0.16	0.15	0.14	0.09	0.12
Days Sales Outstanding TTM	-	-	-	5.64	6.40	6.01	4.64	4.31	6.21	4.57	8.03	6.25
Receivables Turnover TTM	-	-	-	64.69	57.07	60.78	78.61	84.70	58.77	79.92	45.45	58.37
Per Share Metrics
Diluted EPS TTM	-0.54	-0.53	-1.16	-1.10	-1.06	-1.71	-0.52	-0.82	-1.09	-1.27	-1.62	-1.49
Free Cash Flow Per Share TTM	-0.41	-0.39	-0.64	-0.37	-0.39	-0.72	-0.26	-0.91	-1.04	-1.14	-1.29	-1.06
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	76.34%	73.28%	85.62%	85.82%	86.00%	85.09%	89.62%	90.61%	89.00%	89.05%	83.32%	88.29%
Operating Profit Margin TTM	-961.91%	-975.91%	-974.00%	-873.48%	-793.64%	-758.18%	-170.99%	-210.55%	-277.55%	-311.55%	-571.06%	-358.34%
Net Profit Margin TTM	-832.58%	-829.58%	-900.07%	-802.07%	-732.46%	-705.48%	-136.65%	-183.28%	-248.28%	-283.15%	-534.83%	-337.90%
Growth Metrics
Net Revenue Growth (1Y)	-52.93%	-58.19%	-41.87%	-47.56%	-42.87%	-40.09%	26.35%	2.72%	0.95%	5.03%	-8.80%	407.54%
Net Income Growth (1Y)	-46.50%	-50.84%	282.88%	129.47%	68.53%	49.26%	-67.72%	-44.28%	-19.75%	1.81%	39.66%	26.47%
EPS Growth (1Y)	-49.17%	-69.00%	122.89%	33.46%	-2.13%	34.80%	-67.98%	-44.80%	-24.50%	-4.89%	31.50%	18.16%
Valuation Metrics
P/E TTM	-6.93	-5.68	-1.64	-1.29	-1.44	-1.45	-2.22	-1.34	-1.14	-0.83	-4.23	-6.95
P/B TTM	3.36	3.58	1.94	1.32	1.30	1.23	0.63	0.59	0.62	0.47	3.10	4.07
P/S TTM	57.73	47.14	14.80	10.37	10.53	10.24	3.03	2.45	2.83	2.35	22.63	23.50
Market Cap	483.04M	368.92M	232.98M	174.06M	187.26M	191.70M	82.09M	78.42M	88.13M	73.30M	485.03M	732.47M
Enterprise Value	454.38M	348.96M	207.72M	148.66M	156.90M	167.13M	34.44M	55.59M	52.29M	33.42M	445.99M	701.32M
Calculated Values
Free Cash Flow TTM	-52.29M	-47.22M	-78.82M	-45.86M	-48.18M	-56.03M	-18.49M	-65.13M	-73.68M	-79.63M	-91.65M	-74.98M
Net Debt	-28.66M	-19.96M	-25.26M	-25.40M	-30.36M	-24.57M	-47.65M	-22.83M	-35.84M	-39.88M	-39.04M	-31.15M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-04-23Sale

Owner: Leonard, Braden Michael

Title: -

Shares: 300,000

Price/Share: $4.53

Value: $1,359,000.00

Shares Owned: 13,950,000

Relationship: TenPercentOwner

Ownership: Indirect

2024-11-19Purchase

Owner: Mehra, Anand

Title: -

Shares: 666,666

Price/Share: $2.25

Value: $1,499,998.50

Shares Owned: 710,030

Relationship: Director

Ownership: Direct

2024-08-05Purchase

Owner: Leonard, Braden Michael

Title: -

Shares: 206,025

Price/Share: $1.24

Value: $255,471.00

Shares Owned: 14,250,000

Relationship: TenPercentOwner

Ownership: Indirect

2024-07-31Purchase

Owner: Leonard, Braden Michael

Title: -

Shares: 100,000

Price/Share: $1.33

Value: $133,000.00

Shares Owned: 13,876,421

Relationship: TenPercentOwner

Ownership: Indirect

2024-07-22Purchase

Owner: Leonard, Braden Michael

Title: -

Shares: 17,716

Price/Share: $1.33

Value: $23,562.28

Shares Owned: 13,602,691

Relationship: TenPercentOwner

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-04-23	Leonard, Braden Michael	TenPercentOwner	-	Indirect	Sale	300,000	4.53	$1,359,000.00	13,950,000	4
2024-11-19	Mehra, Anand	Director	-	Direct	Purchase	666,666	2.25	$1,499,998.50	710,030	4
2024-08-05	Leonard, Braden Michael	TenPercentOwner	-	Indirect	Purchase	206,025	1.24	$255,471.00	14,250,000	4
2024-07-31	Leonard, Braden Michael	TenPercentOwner	-	Indirect	Purchase	100,000	1.33	$133,000.00	13,876,421	4
2024-07-22	Leonard, Braden Michael	TenPercentOwner	-	Indirect	Purchase	17,716	1.33	$23,562.28	13,602,691	4
2024-07-05	Leonard, Braden Michael	TenPercentOwner	-	Indirect	Purchase	123,017	1.15	$141,469.55	13,447,969	4
2024-07-01	Leonard, Braden Michael	TenPercentOwner	-	Indirect	Purchase	107,434	1.14	$122,474.76	13,095,572	4
2024-06-18	Leonard, Braden Michael	TenPercentOwner	-	Indirect	Purchase	50,000	1.13	$56,500.00	11,552,134	4
2024-06-13	Leonard, Braden Michael	TenPercentOwner	-	Indirect	Purchase	528,621	1.14	$602,627.94	11,007,134	4
2024-03-04	Powell, Andrew Kenneth Wi…	Director	-	Direct	Purchase	6,000	1.25	$7,500.00	28,863	4
2023-10-23	Monahan, Joseph	Officer	Chief Scientific Officer	Direct	Sale	6,000	5.08	$30,480.00	129,724	4
2023-09-06	Balthaser, Kevin	Officer	Chief Financial Officer	Direct	Purchase	9,490	7.90	$74,971.00	15,461	4
2023-08-28	Loerop, James	Officer	Chief Business Officer	Direct	Purchase	14,705	6.80	$99,994.00	21,688	4
2023-08-21	Monahan, Joseph	Officer	Chief Scientific Officer	Direct	Sale	6,000	7.32	$43,920.00	135,724	4
2023-06-20	Monahan, Joseph	Officer	Chief Scientific Officer	Direct	Sale	6,000	10.28	$61,680.00	141,724	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

82.32%

Inst. Shares: 106,034,675

Shares Outstanding: 128,810,050

2025-12-31

67.32%

Inst. Shares: 82,511,682

Shares Outstanding: 122,564,741

2025-09-30

66.75%

Inst. Shares: 81,853,131

Shares Outstanding: 122,619,311

2025-06-30

71.39%

Inst. Shares: 87,508,694

Shares Outstanding: 122,580,967

2025-03-31

72.34%

Inst. Shares: 88,537,483

Shares Outstanding: 122,390,303

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	106,034,675	128,810,050	82.32%
2025-12-31	82,511,682	122,564,741	67.32%
2025-09-30	81,853,131	122,619,311	66.75%
2025-06-30	87,508,694	122,580,967	71.39%
2025-03-31	88,537,483	122,390,303	72.34%
2024-12-31	85,524,073	77,296,665	110.64%
2024-09-30	92,786,928	71,381,731	129.99%
2024-06-30	96,653,148	71,291,400	135.57%
2024-03-31	98,586,146	71,074,858	138.71%
2023-12-31	104,361,074	69,808,855	149.50%
2023-09-30	135,768,536	70,807,934	191.74%
2023-06-30	138,007,774	70,633,528	195.39%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Aclaris Therapeutics, Inc. (ACRS) — SEC Financial Statements & Analysis

Aclaris Therapeutics, Inc. (ACRS) is a pharmaceutical preparations company, incorporated in DE. Aclaris Therapeutics, Inc. trades on Nasdaq as: ACRS. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Aclaris Therapeutics, Inc. reported a -52.93% year-over-year revenue growth, a Gross Profit Margin of 76.34% (TTM), a Debt-to-Equity ratio of 0.38x, a Price-to-Sales (P/S) ratio of 57.73x (TTM), a Price-to-Book (P/B) ratio of 3.36 (TTM), at a market cap of $483.04M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -52.93%
Gross Profit Margin TTM: 76.34%
Debt To Equity: 0.38x
P/S TTM: 57.73x
P/B TTM: 3.36
Market Cap: $483.04M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Aclaris Therapeutics, Inc. in?

Aclaris Therapeutics, Inc. (ACRS) operates in the Pharmaceutical Preparations industry.

What is ACRS's market cap?

Aclaris Therapeutics, Inc. (ACRS) has a market capitalization of $483.04M as of 2026-03-31.

What exchange does ACRS trade on?

Aclaris Therapeutics, Inc. (ACRS) trades on the Nasdaq.

Where is Aclaris Therapeutics, Inc. incorporated?

Aclaris Therapeutics, Inc. is incorporated in DE.

Aclaris Therapeutics, Inc. (ACRS) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.